THE ANALYSIS: JPMorgan analyst Geoff Meacham downgraded Idenix shares to "Neutral" from "Overweight," and cut his price target to $5 per share from $13. He said the delays could fall further behind Gilead Sciences Inc. and other competitors because of the delay. He said the main problem isn't just the delay for IDX20963 itself: the company was planning to test a combination of that drug and IDX719. It can't do that until the FDA's safety concerns are addressed.